Cell News and Research

RSS

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

Stand Up to Cancer awards UNC Lineberger scientist with 13 Innovative Research Grants

Angelique Whitehurst, PhD, assistant professor of pharmacology and a member of UNC Lineberger Comprehensive Cancer Center, has been awarded one of 13 Innovative Research Grants from Stand Up to Cancer, the scientific partner of the American Association of Cancer Research.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Caliper introduces novel fluorescent imaging agent for pre-clinical research

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the launch of XenoLight RediJect COX-2 Probe, a novel fluorescent imaging agent for pre-clinical research that specifically detects the cyclooxygenase-2 biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

5 Apr 2011

Morphotek acquires tumor targeting assets from TMI

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that it has acquired certain assets relating to a proprietary tumor targeting platform from TransMolecular, Inc. for an undisclosed upfront payment and future development milestones.

4 Apr 2011

Aflac announces $1.06 million scholarship awards for cancer research

Aflac, the company that helps employers enhance benefits offerings to employees, today announced it will donate a total of $1,060,000 to the American Association for Cancer Research (AACR) to help defray the costs facing cancer researchers. The three-year scholarship awards focus on career development, scholar-in-training; a special program for high school students, and a task force on pediatric oncology.

4 Apr 2011

Axxora.com to distribute TGR's new ELISAONE technology assay reagents in the US and South America

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.

4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

ImmunoGen presents IMGN853 data against ovarian cancer, carcinomas at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors.

4 Apr 2011

Miltenyi Biotec launches MACSQuant VYB benchtop flow cytometer

Miltenyi Biotec today announces the worldwide release and availability of the MACSQuant VYB, a compact, benchtop flow cytometer featuring violet, yellow, and blue lasers, and detection of 10 optical parameters.

4 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

AtlantiCare to use MEDai's Risk Navigator solutions for patient management

AtlantiCare, the largest health system in southeastern New Jersey, will allow its healthcare providers to better manage patient populations and track clinical and financial objectives with quality-focused tools from Elsevier/MEDai, a leading provider of predictive analytic solutions.

4 Apr 2011

Oral cancer more common among Americans with HPV16 viral infections

A serious change in the cause of oral cancer is taking place nationally, and its implications are impacting the American public in a manner that a decade ago no one would have predicted.

4 Apr 2011

Cancer Discovery to present practice-changing research at AACR meeting

Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.

4 Apr 2011

AACR continues to increase focus on cancer clinical trials

The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year's meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.

4 Apr 2011

Researchers pinpoint effects of enhanced adult neurogenesis in hippocampus

Adult mice engineered to have more newborn neurons in their brain memory hub excelled at accurately discriminating between similar experiences - an ability that declines with normal aging and in some anxiety disorders.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011